A meta-analysis of dizziness as an adverse reaction in novel endocrine therapy for advanced prostate cancer

= 0.0%, p = 0.8165), though statistical significance was not reached. Subgroup analyses by ARPI type (abiraterone [Abi], Abi + enzalutamide [Enz], darolutamide [Dar], Enz) showed no significant differences in dizziness risk among subgroups (p = 0.2026). In conclusion, novel endocrine therapy with ARPIs increases the risk of all-grade dizziness in prostate cancer patients, while the risk of severe dizziness remains non-significant. Clinicians should monitor dizziness symptoms during ARPI treatment to optimize patient management.